Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy

NCT06717412 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2025-04-04

No results posted yet for this study

Summary

Evaluating the Optimal Effective Dose and Safety of Conbercept in Treating Retinopathy of Prematurity (ROP)

Conditions

  • Retinopathy of Prematurity (ROP)

Interventions

DRUG

Conbercept

Administered as an intravitreal injection

Sponsors & Collaborators

  • Wang Yusheng

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-29
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06717412 on ClinicalTrials.gov